04.10.19
YMC Co., Ltd., a supplier of separation resins, services and systems for the pharmaceutical market, has acquired ChromaCon AG of Zurich, Switzerland.
ChromaCon has a portfolio of continuous chromatography technologies and markets laboratory scale separation/purification systems using these technologies. ChromaCon technology offers twin-column purification to increase productivity in both large and small molecule manufacturing.
YMC and ChromaCon have maintained a strategic business alliance with YMC being an exclusive distributor of ChromaCon’s lab-scale systems in Japan and India. ChromaCon had also licensed technologies to YMC Process Technologies for GMP production scale equipment. YMC completed its acquisition of YPT from LEWA-Nikkiso America December 2018. YPT develops and manufactures scale-up separation systems for the pharmaceutical manufacturing industry.
With ChromaCon, YMC has now a fully integrated organization for the development and commercialization of continuous separation/purification systems for biopharmaceutical and pharmaceutical industry from lab to production scale (GMP) manufacturing.
YMC Group is furthering its investment with the expansion of R&D of the continuous separation/purification platform in its Kyoto, Japan, site where YMC is building a new facility, scheduled to start operations in October 2019.
ChromaCon has a portfolio of continuous chromatography technologies and markets laboratory scale separation/purification systems using these technologies. ChromaCon technology offers twin-column purification to increase productivity in both large and small molecule manufacturing.
YMC and ChromaCon have maintained a strategic business alliance with YMC being an exclusive distributor of ChromaCon’s lab-scale systems in Japan and India. ChromaCon had also licensed technologies to YMC Process Technologies for GMP production scale equipment. YMC completed its acquisition of YPT from LEWA-Nikkiso America December 2018. YPT develops and manufactures scale-up separation systems for the pharmaceutical manufacturing industry.
With ChromaCon, YMC has now a fully integrated organization for the development and commercialization of continuous separation/purification systems for biopharmaceutical and pharmaceutical industry from lab to production scale (GMP) manufacturing.
YMC Group is furthering its investment with the expansion of R&D of the continuous separation/purification platform in its Kyoto, Japan, site where YMC is building a new facility, scheduled to start operations in October 2019.